Products for Research Use Only
RegisterLogin

Omigapil

CAT: 0804-HY-16361Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16361Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Omigapil (CGP3466B free base), an orally active GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil has the potential for the research of Alzheimer's disease. Omigapil is a apoptosis inhibitor. Omigapil can be used for the research of congenital muscular dystrophy (CMD) . Omigapil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups[1][2].
CAS Number
181296-84-4
Product Name Alternative
CGP3466B (free base) ; TCH346
UNSPSC
12352005
Target
Apoptosis
Related Pathways
Apoptosis
Field of Research
Metabolic Disease; Inflammation/Immunology; Neurological Disease
Solubility
10 mM in DMSO
Smiles
C#CCN(CC1=CC2=C(OC3=C1C=CC=C3)C=CC=C2)C
Molecular Formula
C19H17NO
Molecular Weight
275.34
References & Citations
[1]Sarina Meinen, et al. Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice. EMBO Mol Med. 2011 Aug;3 (8) :465-79.|[2]Tanusree Sen, et al. Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β. Sci Signal. 2018 Mar 20;11 (522) :eaao6765.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
GTR19274071-01Omigapil
461571-01Omigapil Maleate

Popular Products